COVID-19 Supplemental work: POINT-OF-CARE BIOLOGICAL ASSAY FOR DETERMINING TISSUE-SPECIFIC ABSORBED IONIZING RADIATION DOSE (BIODOSIMETER).

COVID-19 补充工作：用于确定组织特异性吸收电离辐射剂量的护理点生物测定（生物剂量计）。

• 批准号: 10259999
• 负责人: NARESH MENON
• 金额: $ 150万
• 依托单位: CHROMOLOGIC, LLC
• 依托单位国家: 美国
• 财政年份: 2017
• 资助国家: 美国
• 起止时间: 2017-03-01 至 2021-05-10
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10259999
• 关键词: Adult Respiratory Distress Syndrome; Algorithms; Biological Assay; COVID-19; Clinical Trials; Contracts; Diagnosis; Ionizing radiation; MicroRNAs; Patients; Radiation Dose Unit; Tissues; Work; biodosimeter; mortality; outcome prediction; patient stratification; point of care; research clinical testing

The company proposes to develop a rapid clinical test using miRNA signatures to stratify patients diagnosed with COVID-19 by predicting likelihood of: 1) contracting ARDS related to COVID-19; 2) recovering from ARDS; or 3) mortality. The company has identified a panel of miRNAs from 240 normal and 22 ARDS patients, which was able to accurately (>98%) predict outcomes.

该公司提议开发一种使用miRNA签名的快速临床测试，通过预测以下可能性对诊断为COVID-19的患者进行分层：1）感染与COVID-19相关的ARDS; 2）从ARDS中恢复;或3）死亡。 该公司已经从240名正常人和22名ARDS患者中鉴定出一组miRNAs，这些miRNAs能够准确地（>98%）预测结果。